What is the plasma half-life of fluoxymesterone and why does it matter for oral dosing?

Fluoxymesterone carries a plasma half-life of approximately 9–10 hours following oral administration, as documented in clinical pharmacology references. This means the compound reaches roughly half its peak plasma concentration within that window, making single daily dosing inadequate for maintaining consistent exposure. Dividing the total daily amount into two or three spaced administrations is the practical consequence of this elimination rate.

How quickly does fluoxymesterone reach peak plasma concentration after a tablet is taken?

Fluoxymesterone is absorbed in the upper gastrointestinal tract and typically reaches peak plasma concentration (Cmax) within 1–2 hours of oral intake under fasted or lightly-fed conditions. The 5 mg tablet format at Hilma Biocare's HPLC-verified potency ensures that the dose ingested corresponds precisely to the labelled amount, so the pharmacokinetic curve is predictable rather than variable due to content uncertainty.

How does fluoxymesterone's half-life compare to injectable testosterone esters in terms of clearance speed?

Compared to testosterone enanthate — which carries a half-life of approximately 4–5 days — fluoxymesterone clears the body roughly 10 times faster, with parent compound largely eliminated within 24 hours of the final dose. This rapid clearance is useful for pre-competition phase planning but also means that any missed dose creates a pharmacologically meaningful gap in plasma concentration, unlike long-ester injectables which buffer through their depot effect.

Why does Hilma Biocare offer Halotestin at 5 mg per tablet rather than a higher concentration?

The 5 mg per-tablet concentration is the lowest unit strength in the fluoxymesterone tablet group, and it provides the finest granularity for dose construction. Users can build a 10, 15, 20, or 25 mg daily total by combining tablets without needing to cut higher-strength units, which avoids dose-splitting inaccuracies. The 100-tablet pack at this strength also accommodates extended multi-week protocols at conservative daily totals.

Can the Hilma Biocare Halotestin tablets be split to achieve doses below 5 mg, and how are they presented for storage?

The tablets are sealed in a container format designed to maintain integrity through the distribution chain; splitting is mechanically possible but not recommended as the primary dose-management strategy, since the HPLC-verified content guarantee applies to the intact 5 mg tablet unit rather than a fragment. The most precise approach at sub-5 mg ranges is to adjust frequency rather than tablet division, taking one tablet every 12–16 hours instead of a smaller fractional dose more frequently. (2) angle_used

HPLC Verified

Hilma Biocare

Halotestin 5mg/tab 100 Tabletten by Hilma Biocare

Name: Halotestin 5mg/tab 100 Tablets by Hilma Biocare
Brand: Hilma Biocare
SKU: ORA-FLUO-HIL-002
Price: 90.00 EUR
Availability: InStock

Fluoxymesterone — a structurally modified oral androgen — is formulated here at 5 mg per tablet across a 100-tablet pack, with its pharmacokinetic profile characterised by a short plasma half-life of roughly 9–10 hours and rapid gastrointestinal absorption following oral ingestion. Because of that abbreviated elimination window, dosing frequency directly governs circulating plasma concentrations, making precise timing central to consistent pharmacological exposure. Quality is independently confirmed at the finished-tablet stage: every production batch undergoes HPLC potency verification, with LAL endotoxin testing and GMP-certified compression records completing the release dossier.

€90.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Short 9–10 hour plasma half-life enables predictable daily clearance and timing precision
5 mg per-tablet granularity allows stepwise dose construction without volumetric guesswork
HPLC-verified finished-tablet potency confirms instrument-measured content per unit
100-tablet pack provides sufficient supply for a complete multi-week oral protocol
Rapid oral absorption supports pre-activity pharmacological timing strategies
Divided daily dosing schedule enabled by abbreviated elimination window
GMP-certified compression and LAL-tested raw materials underpin batch release integrity

Phase	Daily Dose	Dosing Schedule	Note
Introductory (Weeks 1–2)	10–15 mg/day	2 × 5 mg or 3 × 5 mg, evenly spaced	Establishes baseline plasma exposure; short half-life requires consistent timing
Maintenance (Weeks 3–4)	20 mg/day	2 × 10 mg (2 tablets each) or 4 × 5 mg	Divide to sustain steady-state; avoid single-bolus intake given 9–10 hr half-life
Advanced / Peak (Weeks 5–6, if indicated)	30–40 mg/day	3–4 equally spaced administrations	Maximum recommended duration limited; monitor hepatic markers throughout
Taper / Exit (Final Week)	10 mg/day	2 × 5 mg	Gradual reduction respects rapid clearance; supports PCT timing

Key takeaways

Expect a 9–10 hour plasma half-life; schedule doses accordingly across the day.
Split total daily intake across two or three evenly timed administrations.
Choose 5 mg tablets for the finest incremental dose-building precision available.
Initiate PCT within 24–48 hours of the last tablet thanks to rapid clearance.
Confirm potency via HPLC-verified batch data before committing to a protocol.

Pharmacokinetic Identity of Fluoxymesterone at 5 mg per Tablet

Fluoxymesterone is an orally bioavailable androgen whose defining pharmacokinetic characteristic is a short systemic half-life — documented in clinical pharmacology literature at approximately 9–10 hours following oral administration — that distinguishes its plasma residence time sharply from depot-injected androgens whose half-lives are measured in days or weeks. Hilma Biocare's 5 mg tablet format gives users direct, titratable control over daily dose construction, because incremental 5 mg units can be stacked or split across the day without relying on volume-based estimation. The HPLC-verified per-tablet content ensures that each unit delivers a confirmed, instrument-measured quantity of active compound rather than a theoretical fill figure.

Absorption, Distribution, and Plasma Clearance

Fluoxymesterone reaches peak plasma concentration relatively quickly after oral intake, with absorption occurring in the upper gastrointestinal tract and first-pass hepatic processing contributing to its metabolic load. Plasma protein binding is high — predominantly to sex hormone-binding globulin (SHBG) and albumin — meaning that free (unbound) fluoxymesterone represents only a fraction of the measured total concentration at any given sampling point. Compared to testosterone enanthate, which carries a plasma half-life in the range of 4–5 days, fluoxymesterone clears the system within a single day under normal metabolic conditions, a distinction with direct implications for pre-competition timing strategies and drug-test planning.

Dosing Frequency as a Function of Half-Life

Because a 9–10 hour half-life produces measurable concentration troughs between doses, clinical and performance literature consistently recommends dividing the total daily amount into two or three administrations spaced across waking hours rather than a single bolus intake. Fluoxymesterone undergoes hepatic metabolism primarily via cytochrome P450 enzymes, and urinary metabolites remain detectable well beyond the point of pharmacological inactivity — a pharmacokinetic distinction users must factor into their timing calculations. The 100-tablet pack at 5 mg per unit provides sufficient tablet count to sustain a multi-week protocol without the per-dose imprecision inherent in higher-concentration presentations.

Quality Documentation Underpinning the Release Decision

Every batch of Hilma Biocare Fluoxymesterone 5 mg tablets is released against a compound-specific analytical record: HPLC quantification of finished-tablet potency anchors the content claim to instrument-generated data, LAL (Limulus Amebocyte Lysate) endotoxin screening confirms pyrogen-free status at raw material intake, and GMP-certified compression parameters are logged within the batch-exclusive dossier that travels with each production run from manufacture through release.

Usage

Calculate your daily target dose in 5 mg increments: before beginning — the short plasma half-life of approximately 9–10 hours means that a single daily administration will produce a marked concentration peak followed by a trough; dividing the total dose prevents this.
Space administrations evenly across waking hours: — for a two-dose schedule, aim for a 10–12 hour gap; for three doses, approximately 7–8 hours between each intake aligns with the half-life curve.
Take each tablet with a moderate meal or light snack: to reduce gastrointestinal irritation without significantly blunting absorption kinetics.
Log your administration times daily: — because fluoxymesterone's abbreviated elimination window makes timing drift (e.g., taking a dose 2–3 hours late) pharmacokinetically meaningful in terms of plasma trough depth.
Set a clear cycle end date before you start: — urinary metabolite detection extends well beyond pharmacological inactivity, and the 9–10 hour parent-compound half-life should not be conflated with the detectability window of downstream metabolites.
Initiate PCT promptly after the final tablet: — rapid systemic clearance means that post-cycle therapy agents (e.g., Clomiphene Citrate or Tamoxifen Citrate) can be introduced within 24–48 hours of the last dose, rather than the extended waiting periods required after ester-based injectables.

Warnings

Contraindications

Fluoxymesterone is contraindicated in individuals with existing hepatic impairment, prostate or breast carcinoma, or hypercalcaemia associated with bone metastasis. Women who are pregnant or breastfeeding must not use this compound. Known hypersensitivity to fluoxymesterone or any tablet excipient is an absolute contraindication.

Side Effects

Hepatic stress is the primary dose-dependent concern with all 17α-alkylated oral androgens, including fluoxymesterone; elevated liver enzymes (ALT, AST) are the most frequently reported biochemical finding. Androgenic effects — accelerated scalp hair thinning in genetically predisposed individuals, acne, and increased sebum production — are characteristic of the compound's potency profile. Endogenous testosterone suppression occurs even at lower oral doses and should be anticipated from the outset of any cycle. Cardiovascular risk factors, particularly adverse shifts in HDL/LDL cholesterol ratio, require proactive monitoring.

Monitoring

Liver function panels (ALT, AST, bilirubin, ALP) should be assessed at baseline and at minimum every two weeks during active use. Lipid profiles and haematocrit should be checked at the midpoint of any cycle longer than three weeks. Blood pressure monitoring at home is advisable given the compound's potential to influence vascular tone.

PCT (Post-Cycle Therapy)

The short half-life of fluoxymesterone (~9–10 hours) enables PCT initiation within 24–48 hours of the final dose — a practical advantage over long-ester injectable androgens. A standard SERM-based protocol (Clomiphene Citrate 50 mg/day or Tamoxifen Citrate 20 mg/day for 4 weeks) is commonly employed to support endogenous testosterone recovery after cycle completion.

Frequently asked questions

What is the plasma half-life of fluoxymesterone and why does it matter for oral dosing?: Fluoxymesterone carries a plasma half-life of approximately 9–10 hours following oral administration, as documented in clinical pharmacology references. This means the compound reaches roughly half its peak plasma concentration within that window, making single daily dosing inadequate for maintaining consistent exposure. Dividing the total daily amount into two or three spaced administrations is the practical consequence of this elimination rate.
How quickly does fluoxymesterone reach peak plasma concentration after a tablet is taken?: Fluoxymesterone is absorbed in the upper gastrointestinal tract and typically reaches peak plasma concentration (Cmax) within 1–2 hours of oral intake under fasted or lightly-fed conditions. The 5 mg tablet format at Hilma Biocare's HPLC-verified potency ensures that the dose ingested corresponds precisely to the labelled amount, so the pharmacokinetic curve is predictable rather than variable due to content uncertainty.
How does fluoxymesterone's half-life compare to injectable testosterone esters in terms of clearance speed?: Compared to testosterone enanthate — which carries a half-life of approximately 4–5 days — fluoxymesterone clears the body roughly 10 times faster, with parent compound largely eliminated within 24 hours of the final dose. This rapid clearance is useful for pre-competition phase planning but also means that any missed dose creates a pharmacologically meaningful gap in plasma concentration, unlike long-ester injectables which buffer through their depot effect.
Why does Hilma Biocare offer Halotestin at 5 mg per tablet rather than a higher concentration?: The 5 mg per-tablet concentration is the lowest unit strength in the fluoxymesterone tablet group, and it provides the finest granularity for dose construction. Users can build a 10, 15, 20, or 25 mg daily total by combining tablets without needing to cut higher-strength units, which avoids dose-splitting inaccuracies. The 100-tablet pack at this strength also accommodates extended multi-week protocols at conservative daily totals.
Can the Hilma Biocare Halotestin tablets be split to achieve doses below 5 mg, and how are they presented for storage?: The tablets are sealed in a container format designed to maintain integrity through the distribution chain; splitting is mechanically possible but not recommended as the primary dose-management strategy, since the HPLC-verified content guarantee applies to the intact 5 mg tablet unit rather than a fragment. The most precise approach at sub-5 mg ranges is to adjust frequency rather than tablet division, taking one tablet every 12–16 hours instead of a smaller fractional dose more frequently. (2) angle_used

Manufacturer

Each tablet batch of Hilma Biocare Fluoxymesterone 5 mg passes through a release sequence anchored to compound-specific analytical data rather than a generalised product-family certificate: incoming fluoxymesterone API is subjected to HPLC identity and quantitative potency testing against a certified reference standard; that data is assigned to a batch-exclusive record covering this SKU only; and the finished compressed tablets are re-examined by HPLC after GMP-certified tableting to produce an instrument-derived per-tablet content figure that constitutes the formal release decision. LAL (Limulus Amebocyte Lysate) endotoxin screening is applied at the raw material stage, and the entire analytical chain — from intake testing through finished-product sign-off — is archived in documentation that remains traceable to the physical pack via lot code.

Product details

Brand	Hilma Biocare
Active ingredient	fluoxymesterone
Also known as	Halotestin, Halo, Fluoxymesteron, Hilma Biocare Halotestin
Strength	5 mg
Form	Tabletten
Pack size	100 pieces
Item number	ORA-FLUO-HIL-002

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Halotestin Tablets 5mg/tab 50 Tablets by Genesis

Lab Tested

Halotestin Tablets 5mg/tab 50 Tabletten by Genesis

Fluoxymesterone — the 17α-methyl, 11β-hydroxy, 9α-fluoro derivative of testosterone — is a synthetic androgen whose defining biochemical characteristic is its exceptionally high-affinity binding to the androgen receptor (AR), classifying it among the most potent oral DHT-derived androgens in clinical and performance pharmacology. Each tablet delivers a precisely compressed 5 mg dose of fluoxymesterone API, giving users granular control over androgen receptor stimulation at the lowest available single-unit strength in this compound class. Quality assurance is structured around two independent checkpoints: HPLC quantification of the raw API against a certified fluoxymesterone reference standard, and an LAL-based endotoxin assessment on every released batch — all executed within Genesis GMP-certified production suites.

€60.00

Haloxyl 10mg/tab 50 Tablets by Kalpa Pharmaceuticals

Pharma Grade

Haloxyl 10mg/tab 50 Tabletten by Kalpa Pharmaceuticals

Haloxyl is an oral fluoxymesterone tablet formulated at 10 mg per tablet — a 17α-alkylated androgen engineered to survive hepatic first-pass metabolism and deliver meaningful systemic bioavailability through the gastrointestinal route, a pharmacokinetic property that distinguishes oral androgens from injected counterparts. Where a hypothetical injectable fluoxymesterone preparation would bypass the liver entirely and enter circulation with near-complete absorption, the 17α-alkyl modification on Haloxyl enables oral dosing to achieve clinically relevant plasma exposure despite the metabolic burden of first-pass extraction. Quality is confirmed at every stage of production: HPLC potency testing and LAL endotoxin screening are applied as mandatory release criteria within Kalpa Pharmaceuticals' GMP-aligned manufacturing framework.

€90.00

Halotestin 5mg/tab 100 Tablets by Magnus Pharmaceuticals

Batch Tested

Halotestin 5mg/tab 100 Tabletten by Magnus Pharmaceuticals

Magnus Pharmaceuticals Halotestin supplies fluoxymesterone at 5 mg per tablet in a 100-tablet pack, engineered around the pharmacological reality that androgen receptor downregulation sets the hard boundary on productive cycle length. Uninterrupted androgenic stimulation drives measurable AR density loss through ligand-induced receptor internalization, making scheduled off-cycle periods a physiological requirement rather than a precautionary suggestion. Every production batch is cleared for distribution following sequential HPLC potency verification and LAL endotoxin assessment inside a GMP-certified manufacturing facility operating under current international quality standards.

€110.00

Halotestin 5mg/tab 100 Tablets by Omega Meds

GMP Standard

Halotestin 5mg/tab 100 Tabletten by Omega Meds

Omega Meds Halotestin delivers fluoxymesterone at 5 mg per tablet across a 100-tablet pack — purpose-built for bodybuilders who run multi-compound protocols and need a potent androgenic agent that amplifies the anabolic environment created by companion compounds. At 5 mg per unit, each dose can be scaled in fine increments to match the androgenic pressure already established by the stack, making synergistic fine-tuning practical rather than theoretical. Every batch released by Omega Meds satisfies GMP Standard production requirements; HPLC API content verification and LAL endotoxin screening are completed before any tablet reaches distribution.

€52.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00